Daniel Y. Paik
YOU?
Author Swipe
View article: Supplementary Figure 5 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 5 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 322K, Figure S5. Levels of Rad51 transcript were higher in estrogen supplemented PTEN-null endometrial epithelia.
View article: Supplementary Figure 4 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 4 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 139K, Figure S4. Three-dimensional in vitro model for growth and treatment of PTEN-null epithelia co-cultured with WT endometrial stroma.
View article: Supplementary Figure 3 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 3 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 80K, Figure S3. Decreased levels of Cyp3A4 were detected in estrogen depleted mice.
View article: Supplementary Figure 2 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 2 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 409K, Figure S2. The histology of Olaparib treated estrogen deprived PTEN-null tumors was similar to vehicle treated counterparts and resembled human endometrioid endometrial carcinoma.
View article: Supplementary Figure 5 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 5 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 322K, Figure S5. Levels of Rad51 transcript were higher in estrogen supplemented PTEN-null endometrial epithelia.
View article: Supplementary Figure 2 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 2 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 409K, Figure S2. The histology of Olaparib treated estrogen deprived PTEN-null tumors was similar to vehicle treated counterparts and resembled human endometrioid endometrial carcinoma.
View article: Supplementary Figure 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 422K, Figure S1. Despite Olaparib therapy, PTEN-null endometrial tumors persisted and resembled human endometrial endometrioid cancers.
View article: Supplementary Methods, Figure Legend, Table 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Methods, Figure Legend, Table 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 84K, Supplementary Table S1. Antibodies used for immunostaining.
View article: Data from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Data from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
Earlier in vitro work demonstrated that PARP inhibition induces cell death in PTEN-null endometrial cancer cell lines, but the in vivo therapeutic efficacy of these agents against endometrial cancer remains unknown. Here, we …
View article: Supplementary Figure 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 422K, Figure S1. Despite Olaparib therapy, PTEN-null endometrial tumors persisted and resembled human endometrial endometrioid cancers.
View article: Supplementary Figure 3 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 3 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 80K, Figure S3. Decreased levels of Cyp3A4 were detected in estrogen depleted mice.
View article: Supplementary Methods, Figure Legend, Table 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Methods, Figure Legend, Table 1 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 84K, Supplementary Table S1. Antibodies used for immunostaining.
View article: Data from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Data from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
Earlier in vitro work demonstrated that PARP inhibition induces cell death in PTEN-null endometrial cancer cell lines, but the in vivo therapeutic efficacy of these agents against endometrial cancer remains unknown. Here, we …
View article: Supplementary Figure 4 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i>
Supplementary Figure 4 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition <i>In Vivo</i> Open
PDF file - 139K, Figure S4. Three-dimensional in vitro model for growth and treatment of PTEN-null epithelia co-cultured with WT endometrial stroma.
View article: Supplementary Figure 4 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 4 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 364K, Stromal or epithelial specific deletion of PR-A and PR-B.
View article: Supplementary Figure 6 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 6 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 130K, Analysis of epithelial and stromal populations from PTENKO and PTENKO/Kras tumors.
View article: Supplementary Figure 7 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 7 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 306K, Over-expression of the human progesterone receptor (hPR) with a lentivirus in the tumor stroma.
View article: Supplementary Figure 1 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 1 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 250K, Histology of PTENKO tumors and hormone supplementation in treated mice.
View article: Supplementary Figure 2 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 2 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 188K, Biologic behavior of PTENKO tumors during and after cessation of progesterone therapy.
View article: Supplementary Figure 5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 419K, Activation of Kras concomitant with PTEN loss (PTENKO/Kras) results in endometrial tumors that invade the kidney parenchyma.
View article: Supplementary Figure Legends and Materials and Methods and Tables 1-5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure Legends and Materials and Methods and Tables 1-5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 155K, Supplementary Table 1: Antibodies used for FACS sorting. Supplementary Table 2: Antibodies used for IHC. Supplementary Table 3: Primers used for QPCR. Supplementary Table 4: Antibodies used for Western blotting.Supplementary Ta…
View article: Supplementary Figure 2 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 2 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 188K, Biologic behavior of PTENKO tumors during and after cessation of progesterone therapy.
View article: Supplementary Figure 3 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 3 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 183K, Measurement of proliferative index and ER � expression in PTENKO tumors treated under different hormonal conditions.
View article: Supplementary Figure 5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 419K, Activation of Kras concomitant with PTEN loss (PTENKO/Kras) results in endometrial tumors that invade the kidney parenchyma.
View article: Supplementary Figure 4 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 4 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 364K, Stromal or epithelial specific deletion of PR-A and PR-B.
View article: Supplementary Figure 6 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 6 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 130K, Analysis of epithelial and stromal populations from PTENKO and PTENKO/Kras tumors.
View article: Supplementary Figure Legends and Materials and Methods and Tables 1-5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure Legends and Materials and Methods and Tables 1-5 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 155K, Supplementary Table 1: Antibodies used for FACS sorting. Supplementary Table 2: Antibodies used for IHC. Supplementary Table 3: Primers used for QPCR. Supplementary Table 4: Antibodies used for Western blotting.Supplementary Ta…
View article: Supplementary Figure 1 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 1 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 250K, Histology of PTENKO tumors and hormone supplementation in treated mice.
View article: Data from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Data from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
Progesterone, an agonist for the progesterone receptor (PR), can be an efficacious and well-tolerated treatment in endometrial cancer. The clinical use of progesterone is limited because of the lack of biomarkers that predict hormone sensi…
View article: Supplementary Figure 3 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy
Supplementary Figure 3 from Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy Open
PDF - 183K, Measurement of proliferative index and ER � expression in PTENKO tumors treated under different hormonal conditions.